From: Opinions on registering trial details: a survey of academic researchers
Variables | Total | E-mail available* | E-mail not available | p** | Responders | Non-responders | p |
---|---|---|---|---|---|---|---|
Recruiting status of study | 1500 | 1299 | 201 | 0.15 | 282 | 1017 | 0.68 |
Recruiting | 1375 (91.7) | 1196 (92.1) | 179 (89.0) | 258 (91.5) | 938 (92.23) | ||
Not yet | 125 (8.3) | 103 (7.9) | 125 (8.3) | 24 (8.5) | 79 (7.8) | ||
Type of sponsor | <0.001 | <0.001 | |||||
NIH | 288 (19.2) | 207 (15.9) | 81 (40.3) | 21 (7.4) | 186 (18.3) | ||
Other | 1212 (80.8) | 1092 (84.1) | 120 (59.7) | 261 (92.5) | 831 (81.7) | ||
Study condition according to ICD 10 | <0.001 | 0.03 | |||||
Infections | 69 (4.6) | 64 (4.9) | 5 (2.5) | 22 (7.8) | 42 (4.1) | ||
Oncology | 608 (40.5) | 474 (36.5) | 134 (66.7) | 73 (25.9) | 401 (39.4) | ||
Haematology | 23 (1.5) | 19 (1.5) | 4 (2.0) | 3 (1.1) | 16 (1.6) | ||
Endocrinologic diseases | 85 (5.7) | 79 (6.1) | 6 (3.0) | 21 (7.4) | 58 (5.7) | ||
Psychiatric diseases | 119 (7.9) | 109 (8.4) | 10 (4.9) | 28 (9.9) | 81 (8.0) | ||
Neurologic diseases | 62 (4.1) | 58 (4.6) | 4 (2.0) | 14 (5.0) | 44 (4.3) | ||
Eye | 12 (0.8) | 2 (1.0) | 10 (0.8) | 2 (0.7) | 8 (0.8) | ||
Ear | 2 (0.1) | 2 (0.1) | 0 (0.0) | 1 (0.3) | 1 (0.1) | ||
Cardiovascular diseases | 123 (8.2) | 118 (9.1) | 5 (2.5) | 30 (10.6) | 88 (8.6) | ||
Lung diseases | 59 (3.9) | 53 (4.1) | 6 (3.0) | 10 (3.5) | 43 (4.2) | ||
Digestive diseases | 43 (3.3) | 4 (2.0) | 47 (3.1) | 15 (5.2) | 28 (2.7) | ||
Skin | 19 (1.3) | 18 (1.4) | 1 (0.5) | 3 (1.1) | 15 (1.5) | ||
Musculoskeletal disorders | 51 (3.4) | 48 (3.7) | 3 (1.5) | 12 (4.3) | 36 (3.5) | ||
Urology | 76 (5.1) | 72 (5.5) | 4 (2.0) | 20 (7.1) | 52 (5.1) | ||
Pregnancy | 26 (1.7) | 23 (1.8) | 3 (1.5) | 5 (1.8) | 18 (1.8) | ||
Perinatal disorders | 10 (0.7) | 10 (0.8) | 0 (0.0) | 3 (1.1) | 7 (0.7) | ||
Labour | 2 (0.1) | 2 (0.1) | 0 (0.0) | 1 (0.3) | 1 (0.1) | ||
Trauma | 39 (2.6) | 35 (2.7) | 4 (2.0) | 6 (2.1) | 29 (2.8) | ||
Extern | 1 (0.1) | 1 (0.1) | 0 (0.0) | 1 (0.3) | 0 (0.0) | ||
Other | 67 (4.5) | 61 (4.7) | 6 (3.0) | 12 (4.3) | 49 (4.8) | ||
Study intervention | <0.001 | 0.10 | |||||
Drug | 895 (59.7) | 741 (57.0) | 154 (76.6) | 143 (50.7) | 598 (58.8) | ||
Procedure | 231 (15.4) | 211 (16.2) | 20 (9.9) | 55 (19.5) | 156 (15.3) | ||
Behaviour | 112 (7.5) | 107 (8.2) | 5 (2.5) | 32 (11.3) | 75 (7.4) | ||
Device | 64 (4.3) | 62 (4.8) | 2 (1.0) | 14 (5.0) | 48 (4.7) | ||
Vaccine | 17 (1.1) | 12 (0.9) | 5 (2.5) | 3 (1.1) | 9 (0.9) | ||
Gene therapy | 5 (0.3) | 4 (0.3) | 1 (0.5) | 0 (0.0) | 4 (0.4) | ||
Other/not applicable | 176 (11.7) | 162 (12.5) | 14 (7.0) | 35 (12.4) | 127 (12.5) | ||
Study phase | <0.001 | <0.01 | |||||
Phase I | 137 (9.1) | 113 (8.7) | 24 (11.9) | 19 (6.7) | 94 (9.2) | ||
Phase II | 357 (23.8) | 281 (21.6) | 76 (37.8) | 45 (16.0) | 236 (23.2) | ||
Phase III | 230 (15.3) | 206 (15.9) | 24 (11.9) | 51 (8.1) | 155 (15.2) | ||
Phase IV | 177 (11.8) | 168 (12.9) | 9 (4.5) | 48 (17.0) | 120 (11.8) | ||
Phase I/II | 72 (4.8) | 56 (4.3) | 16 (8.0) | 6 (2.1) | 50 (4.9) | ||
Phase II/III | 43 (2.9) | 35 (2.7) | 8 (4.0) | 6 (2.1) | 29 (2.8) | ||
Not applicable | 484 (32.3) | 440 (33.9) | 44 (21.9) | 107 (37.9) | 333 (32.7) |